Navigation Links
Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
Date:1/28/2008

SAN DIEGO, Jan. 28 /PRNewswire/ -- Cylene Pharmaceuticals has appointed Dr. Kenna Anderes to its management team. Dr. Anderes, who brings 17 years of life sciences research experience with a focus on cancer biology research, will serve as Vice President of Cancer Biology. With Cylene's most advanced compound, quarfloxin (CX-3543), now in Phase II development, Dr. Anderes will be leading Cylene's biology and pre-clinical research teams to advance other targeted small molecule oncology compounds into the clinic during 2008.

"I am excited about the opportunity to advance more of Cylene's novel drug candidates into the clinic," said Dr. Anderes. "These compounds are orally available and have the potential to become effective and convenient therapeutics for cancers that currently lack effective, patient-friendly treatments."

Dr. Anderes joined Cylene from Pfizer, Inc., where she had led large project teams in oncology and cancer biology research over the past twelve years. Prior to her tenure at Pfizer, Dr. Anderes held several group leader and senior scientist positions at major biotechnology and pharmaceutical companies, such as Warner Lambert and Agouron.

"Dr. Anderes has the ideal background and experience to accelerate and expand our product pipeline," said Dr. William G. Rice, Cylene's President and Chief Executive Officer. "Her expertise in cancer biomarkers and imaging, as well as her leadership experience in pharmaceutical research, will enable her to make meaningful contributions to our management team."

Dr. Anderes earned a Ph.D. in pharmacology from the Southern Illinois University School of Medicine, and she performed a postdoctoral research fellowship in pharmacology at the University of California San Diego.

About Cylene Pharmaceuticals, Inc.

Cylene Pharmaceuticals is a private company dedicated to the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening can
'/>"/>

SOURCE Cylene Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
3. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
4. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
5. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
6. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
7. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
8. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
9. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
10. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
11. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Ames, IA (PRWEB) April 16, 2015 ... (CAST) announces that the prestigious 2015 Borlaug CAST ... honored faculty member at Tuskegee University in Alabama. ... by written material; public presentations; and/or the use ... excels in all three areas. As a specialist ...
(Date:4/16/2015)... MOSCOW , April 16, 2015 /PRNewswire/ ... (ChemRar), the Russian pharmaceutical investment and R&D ... announced collaboration for research, development and commercialization ... with the intention to stimulate ... industry.      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     ...
(Date:4/16/2015)...  EMD Serono today announced the US biopharmaceutical ... , appointed Alise Reicin , MD, ... Development.  Dr. Reicin brings extensive research and early/late ... Immunology. She is an accomplished pharmaceutical executive with ... President in various capacities across R&D at MSD ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Dana-Farber ... Cancer Science and Resolution Bioscience, Inc. today announced ... co-develop a novel, blood-based, clinic ready, Next Generation ... (NSCLC). The collaboration is the first to demonstrate ... and ROS1 fusions in blinded plasma samples and ...
Breaking Biology Technology:The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 2Resolution Bioscience announces successful collaboration on a novel, non-invasive, targeted NGS test for lung cancer 3
... - TOPIC: The state of the microRNA market and the ... current and potential impact on drug discovery, molecular, ... Tuesday, March 31, 2009, - TIME: ... - HOST: Christi Bird, Senior Research Analyst, Healthcare, ...
... March 30 BioVex Inc, a company developing new ... and infectious disease, announced today it has raised $40 ... private financing.The placement was led by Forbion Capital Partners, ... Agricole Private Equity, Harris & Harris Group, Innoven Partners, ...
... software for clinical research trials has named Jovianna DiCarlo President ... years experience driving new pharmaceutical therapeutics and devices through the ... to commercialization. , ... Frederick, MD ...
Cached Biology Technology:Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics 2BioVex Raises $40 Million in First Close of Series F Financing 2BioVex Raises $40 Million in First Close of Series F Financing 3Jovianna DiCarlo Named ConsentSolutions, Inc. President & Chief Executive Officer 2
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... inside each cell, a little engine called RNA polymerase II ... the nucleus that get carried to production units in the ... researchers at the University of Michigan Medical School have shown ... for damage. When certain types of damage in DNA halt ...
... LAFAYETTE, Ind. - A biomedical engineer at Purdue University ... that promises to be more effective than standard CPR ... by 25 percent over the current method. A ... a success rate of 5 percent to 10 percent, ...
... (09/05/07)--It is well established that a child,s brain has ... the extent to which such plasticity exists in the ... and Johns Hopkins University have used converging evidence from ... adult visual cortex does indeed reorganize-and that the change ...
Cached Biology News:Enzyme alerts cell's powerful army to repair DNA damage 2Enzyme alerts cell's powerful army to repair DNA damage 3New CPR promises better results by compressing abdomen, not Chest 2New CPR promises better results by compressing abdomen, not Chest 3New CPR promises better results by compressing abdomen, not Chest 4Adult brain can change, study confirms 2
...
... This monoclonal antibody recognizes 30% ... unrelated individuals. It does not ... proteins lacking rheumatoid factor nor with ... be used in ELISA to detect ...
...
Human VEGF R2 (KDR) MAb (Clone 89106)...
Biology Products: